FOI2021/00263: Sareum Holdings collaboration
Case reference FOI2021/00263
Published 26 July 2021
Request
Request Received: 25 May 2021
Sareum Holdings - Investigating the therapeutic potential of TYK2 / JAK1 inhibitor SDC-1801 in severe phase Covid-19
The captioned UKRI funded study is described as 'Collaborative R&D'. Would you please confirm the identities of all parties involved in the collaboration.
https://gtr.ukri.org/projects?ref=83721
Response
Response Sent: 15 June 2021
Project 83721, "Investigating the therapeutic potential of TYK2 / JAK1 inhibitor SDC-1801 in severe phase Covid-19" is a single participant project, with Sareum Limited being the only participant.
The term 'Collaborative R&D' is the project category assigned to the overall competition, however this competition was open to single applicants and collaborative projects.
Information on all the successful projects for the competition UKRI Ideas to Address COVID-19: Innovate UK de minimis Aug 2020 is available as part of the Innovate UK funding competition winners transparency data.
Documents
This is UK Research and Innovation's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.